This indicates that the biorthogonal conjugation of BTZ did not significantly alter the secondary structure and conjugate's binding efficiency to the ACE2 receptor, a critical step in targeting cancer cells (Fig. 1C). This evidence concerns the gene CASC3 and cancer.